HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
2022 Rome Action Plan on Paediatric HIV & TB
Gilead
Gilead, ViiV Healthcare and MSD commit to implement the principles of the Call to Action (CTA)[1] launched on 1st December 2021 by stakeholders[2] involved in studying antiretroviral agents for treatment and prevention of HIV to support greater inclusion of pregnant women and breastfeeding and contribute to a more equitable investigation of new HIV agents.This includes:
26. Committing to complete embryo-fetal development (EFD) studies for new antiretroviral (ARV) drugs by end of Phase 2 clinical trials.
27. Committing at aiming to complete pre- and post-natal development studies (PPND) for new ARV drugs by the time of early Phase 3 clinical trial enrolment.
28. Committing to generate pharmacokinetic (PK) and early safety data in pregnancy for new drugs by end of Phase 3 clinical trial completion, in the assumption that there are no contraindications to use in pregnancy from pre-clinical studies.
[1] Idem 7
[2] Idem 8
Gilead, building on the progress made by removing contraception requirements for ongoing long acting lenacapavir (LEN) prevention studies and allowing women who become pregnant in LEN HIV prevention trials to consent to stay on study drug, commits to:
29. Provide PK and safety data for lenacapavir in lactating and pregnant women from ongoing prevention studies by 2026.
30. Remove contraception requirements from other ongoing and planned treatment studies with LEN, and permit women who become pregnant in LEN trials to remain on study drug upon consent (contingent on supportive safety data for the agent(s) partnered with LEN).
31. Support conducting a dedicated safety study in pregnant women to evaluate potential adverse effects of LEN used for treatment in pregnant women, birth outcomes, and at least short-term follow-up of infants after birth (contingent on supportive safety data for the agent(s) partnered with LEN).
-
All partners commit to:
163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.
164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care.
165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.
166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.
-
Gilead commits to:
230. Prioritizing development of low dose F/TAF tablet for oral suspension (TOS) and completing investigation of low dose F/TAF TOS paediatric dose for children 3-<25kg older than 4 weeks by end of 2025.
231. Supporting generic development, manufacturing, and regulatory approval of the prioritized paediatric low-dose F/TAF paediatric formulation (as needed beyond what is already allowed through the MPP-Gilead licence for TAF).
232. Fulfilling ongoing PSPs and PIPs for lenacapavir with collaboration and feedback from the GAP-f partners and collaborating to evaluate the potential investigation of lenacapavir in children with multi-drug resistant HIV infection.
233. Collaborate on the design of a platform trial and development of appropriate neonatal formulation(s) to assess innovative options to deliver postnatal prophylaxis and evaluate neonatal PK.
234. Collaborate with GAP-f partners to develop an enhanced monitoring and safety data platform for new and existing paediatric ARV drugs.
235. Make publicly available synopses of PSPs, similar to publicly available PIP summaries, for PADO priority products to enable a more transparent clinical trial ecosystem.
-